Photodynamic Therapy for Lung Cancer
Author Information
Author(s): TETSUYA OKUNAKA, HARUBUMI KATO, CHIMORI KONAKA, KINYA FURUKAWA, MASAHIKO HARADA, YUTAKA YAMAMOTO
Primary Institution: Tokyo Medical College
Hypothesis
Can reduced doses of Photofrin administered via bronchial artery infusion effectively treat early-stage lung cancer while minimizing skin photosensitivity?
Conclusion
The study found that all five patients with early-stage lung cancer achieved complete remission without significant skin photosensitivity after receiving low-dose Photofrin via bronchial artery infusion.
Supporting Evidence
- Complete remission was obtained in all five patients with early-stage lung cancers.
- No significant skin photosensitivity was observed in six out of seven patients.
- Patients received a low dose of 0.7 mg/kg of Photofrin.
Takeaway
Doctors used a special light treatment to help five patients with early lung cancer, and all of them got better without getting sunburned from the medicine.
Methodology
Five patients with early-stage lung cancer received 0.7 mg/kg of Photofrin via bronchial artery infusion 48 hours before photodynamic therapy.
Limitations
The study had a small sample size and did not include a control group.
Participant Demographics
All seven patients were men with a mean age of 73 years.
Want to read the original?
Access the complete publication on the publisher's website